A Next-Generation EGFR–HER3-Targeted Antibody–Drug Conjugate Makes a Difference in Lung Cancer Treatment
In this article
The EGFR- and HER3-targeted bispecific antibody–drug conjugate (ADC) iza-brenhas shown striking results in patients with lung cancer harboring non-classical driver mutations.
🔬 Why Does It Matter?
Non-small cell lung cancer (NSCLC) is genetically heterogeneous and requires different treatment approaches. Although TKIs developed for classical EGFR mutations provide substantial benefits, responses remain limited for EGFR exon20ins, HER2, KRAS G12C, BRAF, MET, SMARCA4, RET and similar non-classical mutations .
In this context, the promising efficacy and safety data presented at ASCO 2025 for BL-B01D1 (iza-bren) , a next-generation ADC, are noteworthy for this patient population.
💉 What Is Iza-bren (BL-B01D1)?
- ✔️ Targets EGFR and HER3 as a bispecific antibody
- ✔️ After cellular uptake, releases its topoisomerase I inhibitor payload (Ed-04) through a lysosomal pathway
- ✔️ Immunogenic cell death and DNA damage are the mechanisms through which it destroys tumors
- ✔️ A next-generation SEBA-ADC (Specificity Enhanced Bi-specific Antibody-Drug Conjugate)
- BL-B01D1 is being jointly developed by China-based Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. and US-based SystImmune, Inc. .
-
Baili-Bio (Chengdu), China: Plays an active role in clinical development and manufacturing.
-
SystImmune, Inc. (Redmond, Washington, US): Owns the antibody engineering and SEBA-ADC (Specificity Enhanced Bi-specific Antibody-Drug Conjugate) platform technology.
-
📋 Study Design and Methods
- Phase I-b study
- Participants: Patients with NSCLC harboring driver mutations other than classical EGFR mutations (n=73)
- Included mutations: EGFR exon20ins, HER2, ALK, ROS1, BRAF, KRAS, SMARCA4, MET, RET, NTRK
- Treatment dose: 2.5 mg/kg, 1 dose every 8 days, every 3 weeks (Q3W, D1D8)
📊 Clinical Findings by Subgroup
| 🧬 Mutation | ORR (%) | cORR (%) | DCR (%) | mPFS (months) | mDOR (months) |
|---|---|---|---|---|---|
| EGFR exon20ins / non-classical | 75.0 | 66.7 | 100.0 | NR (≥6.9 months) | NR (≥5.6 months) |
| HER2 mutation | 61.5 | 53.8 | 100.0 | 8.4 (2.1–NR) | 5.7 (4.2–NR) |
| KRAS / BRAF / MET | 40.9 | 27.3 | 72.7 | 6.7 (1.5–NR) | NR |
| ALK / ROS1 / RET | 26.3 | 15.8 | 78.9 | 2.8 (1.3–4.1) | 4.5 (2.7–NR) |
| SMARCA4 | 0.0 | 0.0 | 0.0 | 1.4 (1.3–NR) | — |
| Overall (n=68) | 45.6 | 35.3 | 82.4 | 6.7 (4.1–11.2) | 7.0 (5.6–NR) |
📝 Note: 5 patients were excluded from the analysis because the first follow-up scan had not been performed.
Note: 5 patients were excluded from the analysis because the first follow-up scan had not been performed.
⚠️ Safety Profile
Iza-bren was generally found to be well tolerated . Adverse effects were predominantly hematologic and manageable with supportive care.
- The most common hematologic toxicities (any grade):
- Anemia (87.7%), leukopenia (74.0%), thrombocytopenia (74.0%), neutropenia (72.6%)
- Non-hematologic toxicities:
- Asthenia (42.5%), nausea (41.1%), mucositis (37.0%), diarrhea (32.9%), alopecia (31.5%)
- Grade ≥3 adverse events: Predominantly hematologic; controlled by dose interruption or reduction
- Treatment-related deaths: NONE
- Cases of interstitial lung disease: Only 1 case (Grade 2)
- New safety signals: NONE OBSERVED
📌 Conclusion and Clinical Meaning
In patients with NSCLC harboring non-classical EGFR mutations and other rare driver mutations, iza-bren provided high response rates and disease control , suggesting that it could become an important treatment alternative for this population.
These findings must be confirmed in larger phase II–III studies. Even now, however, it stands out as a promising agent in subgroups in which conventional treatments have limited effectiveness.
Sources
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.